Completed PHASE3 INTERVENTIONAL 3-arm NCT01073605

Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation

A Two Years Multicentre Study of Genotropin Treatment of Short Prepubertal Children With Intra-Uterine Growth Retardation

Sponsor: Pfizer

Conditions Growth Disorders Intrauterine Growth Retardation

Interventions Genotonorm

Updated 7 times since 2017 Last updated: Nov 8, 2010 Started: Jul 31, 1993 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Growth Disorders and Intrauterine Growth Retardation, this trial is completed. The trial is conducted by Pfizer and has accumulated 7 data snapshots since 1993. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Angers, France , Besançon, France , Bordeaux, France , Boulogne, France , Brest, France , Bron, France , Clermont-Ferrand, France , Dijon, France , Grenoble, France and 16 more locations